What Should the FDA Do With the PCSK9 Inhibitor Evolocumab?
( AMGN )
We predict our FDA won't be able to help themselves. In all likelihood, they will allow the star compound of the American College of Cardiology (ACC) 2015 Scientific Sessions, evolocumab (Repatha, Amgen), to come to market without waiting for "hard outcomes." I predict they will do it for a variety ofreasons,chiefof which is the irrefutable fact that it lowers LDL levels to nadirs that only genetically blessed, anorexic, exercise-addicted vegetarians can achieve
why its down
will be the cyber security leader
Will Be Wall Street Big Wig.
The Street: SGYP Drug Better Tolerated Than IRWD * Posted
Shares of Synergy are up on positive plecanatide results, the drug is better tolerated than Linzess, a competing chronic constipation drug already approved and marketed by Ironwood Pharmaceuticals (IRWD - Get Report)
The Street Insider
Cantor Fitzgerad (SGYP) Seen as Attractive Takeout Target
By: Brent Kenell
Fitbit has unbelievable growth and is already profitable, which is a big deal for a newly public company.
The valuation is attractive, too. GoPro (GPRO) and Under Armour (UA) both have slower growth rates, yet
have higher valuations that Fitbit. If Fitbit traded with the same valuation as Under Armour, it would be $72.